Filing Details

Accession Number:
0001209191-21-065229
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-11-17 18:11:00
Reporting Period:
2021-11-15
Accepted Time:
2021-11-17 18:11:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
906709 Nektar Therapeutics NKTR Pharmaceutical Preparations (2834) 943134940
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1789857 Jonathan Zalevsky C/O Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco CA 94158
Chief R&D Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-11-15 40,150 $0.00 252,953 No 4 A Direct
Common Stock Disposition 2021-11-16 20,869 $13.16 232,084 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 12, 2019 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant.
  2. The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on September 15, 2021. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (November 15, 2021) following the date that the performance-based vesting requirement was satisfied.
  3. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  4. This transaction was executed in multiple trades at prices ranging from $12.84 to $13.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer.